Shots:

• AstraZeneca to acquire all outstanding equity of TeneoTwo in exchange for $100M up front. TeneoTwo’s equity holders to receive ~$805M in R&D-related milestones, and ~$360M in commercial-related milestones. The transaction is expected to close in Q3’22
• The acquisition will advance the development of TNB-486 (bispecific CD19 & CD3 T-cell engager, currently in P-I study) for B-cell hematologic malignancies. TNB-486 broadens AstraZeneca's hematology pipeline & includes multiple therapy modalities & mechanisms to target blood cancer that builds on the success of Calquence
• TNB-486 as monothx. or in combination with CD20-targeted therapy can deepen clinical responses & enhance patient outcomes by refocusing the body's natural immune response to target B-cell malignancies

Ref: AstraZeneca | Image: AstraZeneca